How to Evaluate "Research Use Only" Retatrutide Offers as a Compliance-Conscious Owner

Many suppliers market retatrutide as "research use only" or "for laboratory use." Clinic owners often ask whether this creates a safe harbor.

In my experience, simply labeling a product "RUO" does not automatically make clinical use compliant. The FDA has taken the position that products intended for human use — even if labeled otherwise — can still be considered unapproved drugs when used in clinical practice.

• What documentation does the supplier provide regarding intended use and regulatory status?
• Are you being asked to sign agreements that attempt to shift compliance responsibility entirely to your practice?
• How will you document that any use occurs within a legitimate research or IRB-approved protocol (if that is your chosen structure)?
• What is the supplier's own history with regulatory inquiries or warning letters?

From a business and M&A perspective, the cleanest approach is usually to assume that any clinical application of retatrutide will require a formal, documented research framework rather than relying on RUO labeling alone. This protects both your current operations and the future value of the practice.

Related reading: RUO Peptides Guide for Medical Practices · Compounding Pharmacy Due Diligence · Retatrutide Legal Reality 2026 · IRB Enrollment for Practices